Cargando…

Case Report: IBD-like colitis following CAR T cell therapy for diffuse large B cell lymphoma

Chimeric antigen receptor (CAR) T cell therapy has become a new mainstay in the treatment of several hematologic malignancies, but the spectrum of associated complications is still incompletely defined. Here, we report the case of a 70-year-old female patient treated with tisagenlecleucel for diffus...

Descripción completa

Detalles Bibliográficos
Autores principales: Zundler, Sebastian, Vitali, Francesco, Kharboutli, Soraya, Völkl, Simon, Polifka, Iris, Mackensen, Andreas, Atreya, Raja, Neurath, Markus F., Mougiakakos, Dimitrios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10240064/
https://www.ncbi.nlm.nih.gov/pubmed/37284193
http://dx.doi.org/10.3389/fonc.2023.1149450
Descripción
Sumario:Chimeric antigen receptor (CAR) T cell therapy has become a new mainstay in the treatment of several hematologic malignancies, but the spectrum of associated complications is still incompletely defined. Here, we report the case of a 70-year-old female patient treated with tisagenlecleucel for diffuse large B cell lymphoma (DLBCL), who developed chronic diarrhea with characteristics of inflammatory bowel disease (IBD)-like colitis. CAR T cells were substantially enriched in the colon lamina propria and other diagnoses were ruled out. Thus, we conclude that IBD-like colitis in this patient was associated to CAR T cell therapy and needs to be considered as a rare potential complication.